News

The results were from stage one of a two-stage phase II trial of ispinesib administered as monotherapy in the treatment head and neck cancer. This two-stage clinical trial

The agreement gives Shire exclusive worldwide rights to develop tissue protective cytokines (TPCs) in non-nervous system indications, including renal and genetic disease areas. TPCs are modifications of erythropoietin

Under terms of the agreement, UCB will receive upfront and additional payments for development and commercial milestones in excess of $200 million dollars. Furthermore, Biogen Idec will contribute

Adecatumumab (MT201) is being developed in collaboration between Micromet and Serono. The product candidate was assessed as a single agent for efficacy and safety in patients. Serono commented

The talks to acquire Vision Systems (VSL) come after rival bidder Cytyc proposed an offer of $692 million. It has raised its bid to $3.25 a share, up

Xelox has been developed as a treatment for colorectal cancer and includes the oral Xeloda and an infusion of the chemotherapy drug oxaliplatin. The data also showed that

Under terms of the agreement, Takeda is responsible for all development and commercialization activities in the licensed territories. Xenon will receive an upfront cash payment of up to

Peramivir also improved survival rates in animal subjects who were infected with the H5N1 strain of the virus – a potentially vital discovery in the attempt to find

The transaction has been structured as a two-step acquisition comprised of a cash tender offer for all of the outstanding Myogen common stock at $52.50 per share, followed